Eiger Bio Pharmaceuticals To Focus On Metabolic Diseases With Avexitide; David Apelian Takes Helm As CEO
Eiger Bio Pharmaceuticals To Focus On Metabolic Diseases With Avexitide; David Apelian Takes Helm As CEO
06/29/23, 12:03 PM
Location
palo alto
Position
chief executive officer
Eiger BioPharmaceuticals, Inc. , a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare diseases, today announced that following an extensive portfolio prioritization review, the Company will focus its development efforts on advancing avexitide in hyperinsulinemic hypoglycemia indications. The Company will continue to commercialize Zokinvy® for the treatment of Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies
Company Info
Location
palo alto, california, united states
Additional Info
Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for are diseases. Eiger's lead product candidate, avexitide, is a well characterized, first-in-class GLP-1 antagonist for the treatment of post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (HI). Avexitide is the only drug in development for PBH with Breakthrough Therapy designation from the FDA.
For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.